NCT Number: NCT00679718
A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease
To evaluate the efficacy and safety of INS365 Ophthalmic Solution when applied topically in patients with moderate to severe dry eye disease.
Looking for future studies?
Notify MeKey information
Study type
Interventional
Phase
Phase 2
Who can participate
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Best corrected visual acuity of at least +0.7 ETDRS
- Six month history of dry eye disease
- Mild severity in two out of five symptoms
- Unanesthetized Schirmer score of less than or equal to 7mm
- Corneal fluorescein staining greater than or equal to 4 out of 15 or lissamine green conjunctival staining of greater than or equal to 5 out of 18
Exclusion criteria
- Nasal stimulated Schirmer score of less than 3mm
- Have ongoing ocular infection
- Have congenitally absent meibomian or lacrimal glands
- Have had punctal occlusion within a specified time prior to study
- Wear contact lens and refuse to remove them
- Have other excluded eye conditions.
Treatment and study plan
Primary outcomes
-
Schirmer scores
-
Corneal staining
-
Conjunctival staining
-
Tear break-up time
-
Change in artificial tear usage
-
Patient-reported improvement of foreign body sensation
Secondary outcomes
-
Visual acuity
-
Investigator global severity assessment
-
Patient-reported dry eye symptoms other than foreign body sensation
-
Biomicroscopy
-
Ophthalmoscopy
-
IOP
Sponsors and collaborators
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Registry information
Official study title
A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Patients With Moderate to Severe Dry Eye Disease
Important dates
- Study start
- 2000
- Primary completion
- 2000
- Study completion
- 2000
- First posted
- May 19, 2008
- Registry last updated
- Aug 27, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
An Evaluation of the Safety and Tolerability of Ocular Lubricants
NCT07238699
Dry Eye Disease, Dry Eye Syndromes
Sydney, New South Wales, Australia
View Trial DetailsA Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
NCT07025811
Dry Eye Disease, Dry Eye Syndromes
Newport Beach, California, United States
View Trial DetailsA Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
NCT07128628
Dry Eye Disease, Dry Eye Syndromes
Phoenix, Arizona, United States
View Trial DetailsEvaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
NCT07264517
Autoimmune Diseases, Dry Eye Disease
Glendale, California, United States
View Trial Details